Latest From Kyn Therapeutics
While the proposed Bristol/Celgene merger nears an April vote, Celgene continues a recent spate of deal-making, paying $25m up front to Exscientia to discover small molecule candidates for cancer and autoimmune disease.
Genentech will pay $120m up front to co-develop Xencor’s preclinical IL-15 candidate; deal also includes IL-15 R&D. Taiho licenses lung cancer candidate to Cullinan; Celgene and Triphase partner again.
Just two weeks after agreeing on a merger with Bristol, Celgene is back at its own deal-making, signing cancer-focused R&D pacts with Kyn and Obsidian. Boehringer and Bioharmony collaborate on novel therapies for hospital-acquired infections, while Sanofi teams with Biomunex on bi- and multi-specific antibodies.
There is a unique phenomenon being realized in immuno-oncology deal-making compared with other segments in the life sciences sector – an apparent uncoupling between risk and return on invested capital, as early assets provide similar liquidity to more mature assets.
- Therapeutic Areas
- North America
- Company Type
- Parent & Subsidiaries
- Kyn Therapeutics
- Senior Management
Mark Manfredi, PhD, Pres. & CEO
Douglas Carlson, CFO
Michelle Zhang, PhD, VP, R&D
Jeffrey Ecsedy, PhD, CSO
Maude Tessier, PhD, VP, Bus. Dev.
Jason Sager, MD, CMO
- Contact Info
Phone: (857) 273-8343
50 Northern Ave.
Boston, MA 02210
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.